Tuesday, September 24, 2024–11:30 a.m.
-News Release-
AdventHealth Redmond recently utilized a newly FDA-approved device to treat coronary artery disease, securing its place as the first hospital in Georgia to use the innovative technology.
The AGENT™ Drug-Coated Balloon (DCB) helps treat a heart issue called coronary in-stent restenosis (ISR). This happens when an artery that was previously opened with a stent gets narrow again because of plaque or scar tissue. After the artery is prepared, the balloon is put in, and releases a medicine called paclitaxel to the artery wall to stop it from getting narrow again. The U.S. Food and Drug Administration (FDA) approved this device in 2024, making it the first drug-coated balloon for heart arteries in the U.S.
“Our team at AdventHealth Redmond provides whole-person care in every sector of the hospital, and implementing technologies like the AGENT™ Drug-Coated Balloon is one of the many innovations our care team delivers to pave the way as our region’s heart care leaders,” said Isaac Sendros, president and CEO of AdventHealth Redmond.
By delivering medication locally to the site of restenosis using the AGENT™ DCB, there is reduced likelihood to intervene in this segment, significantly improving patient outcomes.
“This is a huge step forward in the treatment of an important problem for the residents of northwest Georgia and northeast Alabama and we’re proud that Adventhealth Redmond was chosen to be the first site in Georgia to use this technology,” said Charles Jackson, MD, cardiologist at AdventHealth Redmond.
For more information about AdventHealth Redmond or its heart care services visit: GeorgiaHeartExperts.com.
